Skip to main content

Myriad Genetics (MYGN) Beats Estimates

Myriad Genetics Inc. (MYGN) recorded an EPS of 54 cents in the fourth quarter of 2010, surpassing the Zacks Consensus Estimate of 33 cents and 24 cents in the year-ago period. For the full year 2010, the company recorded 79% growth in EPS to $1.54, beating the Zacks Consensus Estimate of $1.32 per share. Results in [...]
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.